All updates
All updates
today 39文献与产业新闻精选评分5757 中文产业新闻Chinese source评分6565 海思科2026年第5笔BD落地，临床前自免新药超15亿美元出海
中文产业新闻Chinese source评分6565 海思科将临床前自免资产以近15亿美元授权给Sentivera
文献与产业新闻评分2525 Baxter issues recall of 2 products after particulate concerns resurface
文献与产业新闻评分1919 JATT mastermind launches latest biotech-focused SPAC via $60M IPO
文献与产业新闻评分1818 Boston Scientific hit by cyberattack causing ‘disruptions’ to parts of its business
文献与产业新闻精选评分5555 SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launch
文献与产业新闻评分3030 STAT+: Sword Health to acquire Headspace, according to filing
文献与产业新闻评分1010 Pilkington departs HSBC for NatWest’s new venture team
文献与产业新闻评分1616 After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platform
文献与产业新闻评分1818 Teva faces fresh antitrust scrutiny, this time via competition probe in Turkey
文献与产业新闻评分2525 STAT+: After a years-long slump, Massachusetts biopharma sector has come roaring back in 2026
中文产业新闻Chinese source评分6363 罗氏与韩美药业达成最高23亿美元授权合作，引进非GLP-1减重候选药HM17321
文献与产业新闻评分4747 McKesson strikes $2.25B deal to snap up Precision Medicine Group
文献与产业新闻精选评分5757 McKesson strikes $2.25B deal to snap up Precision Medicine Group
文献与产业新闻评分3737 Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
文献与产业新闻评分77 NAD reaches split decision on hair ad row between Kenvue and Hims & Hers
文献与产业新闻评分2121 Lundbeck strikes expanded pact with Eversana to broaden AI scope across US commercial business
文献与产业新闻评分1717 Moderna vaccine, Genentech obesity deal, Trump’s FDA pick — a BioCentury podcast
文献与产业新闻精选评分5858 Roche adds Hanmi’s obesity asset via licensing agreement: Deals Report
文献与产业新闻评分66 Lilly covers lifelong obesity journey in new GLP-1 Medicaid access campaign
文献与产业新闻评分1313 STAT+: Lady Gaga and her fiancé launch a biotech startup
文献与产业新闻评分3535 Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdict
中文产业新闻Chinese source评分6565 罗氏旗下基因泰克获韩美 UCN2 类似物 HM17321 独家许可，总额最高约 23 亿美元
中文产业新闻精选Chinese source评分6969 基因泰克23亿美元引进韩美药业增肌减脂新药HM17321
中文产业新闻Chinese source评分6363 基因泰克从韩美药业引进减重候选药HM17321，交易总额最高约23亿美元
中文产业新闻精选Chinese source评分7171 益普生完成17.5亿美元收购Kartos，获Ⅲ期口服MDM2抑制剂navtemadlin
中文产业新闻Chinese source评分6464 韩美制药将肌肉保留型肥胖候选药HM17321以23.05亿美元授权基因泰克
中文产业新闻Chinese source评分6363 基因泰克获韩美药品新型减肥药权利 交易额23亿美元
文献与产业新闻评分1212 Qiagen appoints new chief executive after 9-month search
文献与产业新闻评分1616 TME holds onto $1B dream for brain cancer drug as search for partners nears conclusion
文献与产业新闻评分4242 Cellares CEO seeks to 'resize' company after loss of 'large' cell therapy manufacturing customer
文献与产业新闻精选评分6565 Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
文献与产业新闻评分4747 Daiichi Sankyo promotes Ken Keller to lead new commercialization unit
文献与产业新闻评分4545 Lundbeck continues neuroscience evolution as CEO keeps company ‘punching above its weight’
文献与产业新闻评分3030 Community Health Media drives 'credible medical expertise' through physician-led content
文献与产业新闻评分4848 Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug
文献与产业新闻评分2727 Regeneron podcast turns science learnings into immersive experience